Preference for pharmaceutical formulation and treatment process attributes.

Stewart, Katie D; Johnston, Joseph A; Matza, Louis S; Curtis, Sarah E; Havel, Henry A; Sweetana, Stephanie A; Gelhorn, Heather L

Stewart, Katie D; Johnston, Joseph A; Matza, Louis S; Curtis, Sarah E; Havel, Henry A; Sweetana, Stephanie A; Gelhorn, Heather L.

Afiliação

Stewart KD; Outcomes Research, Evidera, Bethesda, MD, USA.
Johnston JA; Global Patient Outcomes & Real World Evidence.
Matza LS; Outcomes Research, Evidera, Bethesda, MD, USA.
Curtis SE; Global Patient Outcomes & Real World Evidence.
Havel HA; Small Molecule Design and Development, Eli Lilly & Company, Indianapolis, IN, USA.
Sweetana SA; Small Molecule Design and Development, Eli Lilly & Company, Indianapolis, IN, USA.
Gelhorn HL; Outcomes Research, Evidera, Bethesda, MD, USA.

Patient Prefer Adherence ; 10: 1385-99, 2016.

Article em En | MEDLINE | ID: mdl-27528802

Palavras-chave

conjoint; contingent valuation; pharmaceutical formulation; preference; treatment process; utility

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Systematic_reviews Aspecto: Patient_preference Idioma: En Revista: Patient Prefer Adherence Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google